A clinical study to evaluate the effect of HDP-101 to treat multiple myeloma.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs HDP 101 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 12 Apr 2017 According to a Wilex AG media release, company plans to initiate this study in late 2018.
- 30 Jan 2017 New trial record